Genotyping versus phenotyping of non-ABO erythrocyte antigens in patients with the Mediterranean hemopathic syndromes: Effect of transfusion therapy.

The Mediterranean hemopathic syndromes (MHS) are the most prevalent hemoglobinopathies in the Mediterranean basin. Transfusion therapy is the main therapy for these disorders, particularly for severe forms of the disease. Currently, pre-transfusion serological typing of erythrocyte antigens is the s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Eman NasrEldin, Safaa A A Khaled, Nada O Abdelhameed, Maha Atwa, Marwa M Thabet, Khalid I Elsayh, Sahar A Elgammal
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/9f94287ce6f045ef8cbf3a8b5764b384
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9f94287ce6f045ef8cbf3a8b5764b384
record_format	dspace
spelling	oai:doaj.org-article:9f94287ce6f045ef8cbf3a8b5764b3842021-12-02T20:05:12ZGenotyping versus phenotyping of non-ABO erythrocyte antigens in patients with the Mediterranean hemopathic syndromes: Effect of transfusion therapy.1932-620310.1371/journal.pone.0251576https://doaj.org/article/9f94287ce6f045ef8cbf3a8b5764b3842021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0251576https://doaj.org/toc/1932-6203The Mediterranean hemopathic syndromes (MHS) are the most prevalent hemoglobinopathies in the Mediterranean basin. Transfusion therapy is the main therapy for these disorders, particularly for severe forms of the disease. Currently, pre-transfusion serological typing of erythrocyte antigens is the standard tool for reducing complications of transfusion in those patients. This study compared genotyping with phenotyping of non-ABO erythrocyte antigens in patients with MHS and assessed the effect of transfusion therapy on their results. One-hundred ninety-eight MHS patients were recruited, screened, and proven negative for allo-antibodies. They were grouped into two groups: (1) 20 newly diagnosed patients with no transfusion history and (2) 178 previously diagnosed patients undergoing transfusion therapy. Patients were interviewed and clinically examined. Full blood count (FBC) and high performance liquid chromatography (HPLC) were done for group 1 only. Genotyping and phenotyping of non-ABO erythrocyte antigens were performed for group 1, and 25 patients out of group 2 were propensity score-matched (PSM) with group 1. Both groups were gender and age matched; 55% and 74% of groups 1 and 2 had major disease, respectively. Insignificant differences were observed between genotyping and phenotyping of non-ABO erythrocyte antigens in group 1, while significant discrepancies and mixed field results were noted in group 2 patients. Discrepancies were obvious with JKa, JKb, and little c antigens. Conclusively, molecular typing is a powerful tool for pre-transfusion testing in chronically transfused MHS patients. This testing reduces incidence of transfusion reactions. JKa, JKb and little c antigens are the most clinically significant non-ABO erythrocyte antigens.Eman NasrEldinSafaa A A KhaledNada O AbdelhameedMaha AtwaMarwa M ThabetKhalid I ElsayhSahar A ElgammalPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 7, p e0251576 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Eman NasrEldin Safaa A A Khaled Nada O Abdelhameed Maha Atwa Marwa M Thabet Khalid I Elsayh Sahar A Elgammal Genotyping versus phenotyping of non-ABO erythrocyte antigens in patients with the Mediterranean hemopathic syndromes: Effect of transfusion therapy.
description	The Mediterranean hemopathic syndromes (MHS) are the most prevalent hemoglobinopathies in the Mediterranean basin. Transfusion therapy is the main therapy for these disorders, particularly for severe forms of the disease. Currently, pre-transfusion serological typing of erythrocyte antigens is the standard tool for reducing complications of transfusion in those patients. This study compared genotyping with phenotyping of non-ABO erythrocyte antigens in patients with MHS and assessed the effect of transfusion therapy on their results. One-hundred ninety-eight MHS patients were recruited, screened, and proven negative for allo-antibodies. They were grouped into two groups: (1) 20 newly diagnosed patients with no transfusion history and (2) 178 previously diagnosed patients undergoing transfusion therapy. Patients were interviewed and clinically examined. Full blood count (FBC) and high performance liquid chromatography (HPLC) were done for group 1 only. Genotyping and phenotyping of non-ABO erythrocyte antigens were performed for group 1, and 25 patients out of group 2 were propensity score-matched (PSM) with group 1. Both groups were gender and age matched; 55% and 74% of groups 1 and 2 had major disease, respectively. Insignificant differences were observed between genotyping and phenotyping of non-ABO erythrocyte antigens in group 1, while significant discrepancies and mixed field results were noted in group 2 patients. Discrepancies were obvious with JKa, JKb, and little c antigens. Conclusively, molecular typing is a powerful tool for pre-transfusion testing in chronically transfused MHS patients. This testing reduces incidence of transfusion reactions. JKa, JKb and little c antigens are the most clinically significant non-ABO erythrocyte antigens.
format	article
author	Eman NasrEldin Safaa A A Khaled Nada O Abdelhameed Maha Atwa Marwa M Thabet Khalid I Elsayh Sahar A Elgammal
author_facet	Eman NasrEldin Safaa A A Khaled Nada O Abdelhameed Maha Atwa Marwa M Thabet Khalid I Elsayh Sahar A Elgammal
author_sort	Eman NasrEldin
title	Genotyping versus phenotyping of non-ABO erythrocyte antigens in patients with the Mediterranean hemopathic syndromes: Effect of transfusion therapy.
title_short	Genotyping versus phenotyping of non-ABO erythrocyte antigens in patients with the Mediterranean hemopathic syndromes: Effect of transfusion therapy.
title_full	Genotyping versus phenotyping of non-ABO erythrocyte antigens in patients with the Mediterranean hemopathic syndromes: Effect of transfusion therapy.
title_fullStr	Genotyping versus phenotyping of non-ABO erythrocyte antigens in patients with the Mediterranean hemopathic syndromes: Effect of transfusion therapy.
title_full_unstemmed	Genotyping versus phenotyping of non-ABO erythrocyte antigens in patients with the Mediterranean hemopathic syndromes: Effect of transfusion therapy.
title_sort	genotyping versus phenotyping of non-abo erythrocyte antigens in patients with the mediterranean hemopathic syndromes: effect of transfusion therapy.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/9f94287ce6f045ef8cbf3a8b5764b384
work_keys_str_mv	AT emannasreldin genotypingversusphenotypingofnonaboerythrocyteantigensinpatientswiththemediterraneanhemopathicsyndromeseffectoftransfusiontherapy AT safaaaakhaled genotypingversusphenotypingofnonaboerythrocyteantigensinpatientswiththemediterraneanhemopathicsyndromeseffectoftransfusiontherapy AT nadaoabdelhameed genotypingversusphenotypingofnonaboerythrocyteantigensinpatientswiththemediterraneanhemopathicsyndromeseffectoftransfusiontherapy AT mahaatwa genotypingversusphenotypingofnonaboerythrocyteantigensinpatientswiththemediterraneanhemopathicsyndromeseffectoftransfusiontherapy AT marwamthabet genotypingversusphenotypingofnonaboerythrocyteantigensinpatientswiththemediterraneanhemopathicsyndromeseffectoftransfusiontherapy AT khalidielsayh genotypingversusphenotypingofnonaboerythrocyteantigensinpatientswiththemediterraneanhemopathicsyndromeseffectoftransfusiontherapy AT saharaelgammal genotypingversusphenotypingofnonaboerythrocyteantigensinpatientswiththemediterraneanhemopathicsyndromeseffectoftransfusiontherapy
_version_	1718375499198103552

Genotyping versus phenotyping of non-ABO erythrocyte antigens in patients with the Mediterranean hemopathic syndromes: Effect of transfusion therapy.

Ejemplares similares